Intensive care medicine department, at Saint Louis hospital, France.
Prof. Elie Azoulay is a distinguished French intensivist and the Director of the Critical Care Department at Hôpital Saint-Louis in Paris. He is renowned for his pioneering work in managing critically ill immunocompromised patients. As the founder and director of Nine-I, a multinational group focusing on immunocompromised patients, and co-director of the Famirea Study Group, he has significantly advanced research in intensive care medicine. His leadership extends to founding GRRR-OH, a French multicenter group dedicated to critically ill immunocompromised patients. Prof. Azoulay’s academic contributions are further highlighted by his role as Editor-in-Chief of Intensive Care Medicine from 2012 to 2018, during which the journal’s impact factor rose from 5 to 18. He has also served as President of the European Society of Intensive Care Medicine and is an advisory board member for The Lancet Respiratory Medicine.
Professional Profile
Scopus
ORCID
Google Scholar
🎓 Education
Prof. Azoulay’s academic journey began at Paris VI University (Sorbonne), where he earned his MD in 1991. He furthered his expertise with a Master’s degree in Respiratory Physiology from Paris XII University in 1995. In 2002, he completed his PhD in Respiratory Physiology at Paris VII University (Descartes). His commitment to advancing medical science led him to obtain Habilitation to Conduct and Lead Research from Paris VII University in 2003. Additionally, he holds a University Diploma in Critical Care Management of Immunocompromised Patients from Université Paris Cité, obtained in 2012. His educational background underscores his dedication to both clinical excellence and research innovation in intensive care medicine.
💼 Experience
Prof. Azoulay has an extensive career in intensive care medicine, beginning as a medical intern at Bichat-Claude Bernard Hospital in Paris. He has held significant positions, including serving as a professor of medicine at Paris VII University since 2004. His leadership roles encompass founding and directing several research groups, such as GRRR-OH and Nine-I, focusing on critically ill immunocompromised patients. He has been actively involved in various committees, including the Strategy Committee of the Hospital Group in Paris and the Medical Staffing Group. Prof. Azoulay’s editorial contributions are notable, having served as Editor-in-Chief of Intensive Care Medicine and as an associate editor for prominent journals like Critical Care Medicine and American Journal of Respiratory and Critical Care Medicine. His work has significantly influenced the field of intensive care medicine, particularly concerning immunocompromised patients.link.springer.com
🔬 Research Interests
Prof. Azoulay’s research primarily focuses on the management of critically ill immunocompromised patients, particularly those with hematological malignancies or undergoing immunosuppressive therapies. His work addresses acute respiratory failure, infections, and the psychosocial impact on patients and their families. He has led multicenter studies on the outcomes of intensive care in immunocompromised patients and the prevalence of ICU-related conflicts. His research also delves into the prevention of mental health disorders in ICU settings and the development of strategies to support family members of critically ill patients. Through his interdisciplinary approach, Prof. Azoulay aims to enhance patient care and outcomes in intensive care units.
🏆 Awards
Prof. Azoulay’s exceptional contributions to intensive care medicine have been recognized with several prestigious awards. In 2021, he received the International KJF Award, acknowledging his significant impact on critical care research. His editorial leadership has been instrumental in elevating the impact factor of Intensive Care Medicine. Additionally, his involvement in various international research initiatives has garnered him recognition from global medical communities. These accolades reflect his dedication to advancing the field of intensive care medicine and improving patient outcomes worldwide.rigshospitalet.dk
📚 Top Noted Publications
Prof. Azoulay has authored over 1,200 publications, contributing extensively to the field of intensive care medicine. Notable among his works is the 2019 study on acute respiratory failure in immunocompromised adults, published in The Lancet Respiratory Medicine, which has been cited over 1,000 times. His 2022 research in JAMA on post-traumatic stress symptoms in family members of ICU patients has also garnered significant attention. These publications reflect his commitment to addressing both clinical and psychosocial aspects of critical care. His work continues to influence practices and policies in intensive care units globally.
📌 1. Outcomes in Immunocompromised Patients with Acute Hypoxemic Respiratory Failure Treated by High-Flow Nasal Oxygen
Journal: Intensive Care Medicine
Date: April 2025
DOI: 10.1007/s00134-025-07890-5
Authors: Elie Azoulay, Mélanie Métais, Virginie Lemiale, Djamel Mokart, et al.
Summary:
This multicenter study evaluates the effectiveness and outcomes of high-flow nasal oxygen (HFNO) in immunocompromised patients with acute hypoxemic respiratory failure (AHRF). Key findings suggest that early initiation of HFNO is associated with improved survival, particularly in hematologic patients. It supports HFNO as a frontline noninvasive respiratory support strategy in this vulnerable population.
📌 2. Correction: HELLO – A Protocol for a Cluster RCT to Enhance ICU Team Cohesion
Journal: Intensive Care Medicine Experimental
Date: January 2025
DOI: 10.1186/s40635-024-00702-y
Authors: Elie Azoulay, Nancy Kentish Barnes, Sheila Nainan Myatra, et al.
Summary:
This correction addresses minor protocol amendments in the HELLO trial, aimed at improving interpersonal relationships and teamwork among ICU professionals. The original trial focuses on evaluating whether targeted interventions can reduce burnout and enhance job satisfaction, thus improving team-based care delivery.
📌 3. Lack of Up-to-Date Studies and Data Conversion May Lead to Biased Results: A Response to Wang et al.
Journal: Critical Care
Date: December 2024
DOI: 10.1186/s13054-024-05223-4
Authors: Ali Ait Hssain, Amir Vahedian-Azimi, Elie Azoulay, et al.
Summary:
A scholarly rebuttal to a prior publication, emphasizing the importance of timely and context-relevant data in intensive care research. The authors argue that reliance on outdated studies and improper data interpretation can introduce significant bias in clinical decision-making and policy formulation.
📌 4. Complement System Activation: Bridging Physiology, Pathophysiology, and Therapy
Journal: Intensive Care Medicine
Date: November 2024
DOI: 10.1007/s00134-024-07611-4
Authors: Elie Azoulay, Julien Zuber, Djillali Annane, et al.
Summary:
A comprehensive review of complement system activation in critically ill patients, exploring its dual role in host defense and inflammatory damage. The paper highlights novel therapeutic targets and the need for individualized modulation in conditions like sepsis and ARDS.
📌 5. Treatment of Invasive Pulmonary Aspergillosis and Candidiasis in ICU Patients
Journal: American Journal of Respiratory and Critical Care Medicine
Date: November 2024
DOI: 10.1164/rccm.202410-2045ST
Authors: Oleg Epelbaum, Elie Azoulay, et al.
Summary:
This ATS Clinical Practice Guideline outlines evidence-based recommendations for diagnosing and treating invasive fungal infections in ICU settings. It provides a framework for empirical and targeted antifungal therapy, addressing the rising concern of fungal superinfections in critical care.
Conclusion
Professor Elie Azoulay is an outstanding candidate for the Research for Hypothesis Achievement Award. His pioneering work in the intensive care management of immunocompromised patients, groundbreaking contributions to mental health in ICU survivors and their families, and leadership in multicenter, hypothesis-driven trials position him as a globally respected clinician-scientist. His profile aligns deeply with the intent of the award—translating complex hypotheses into high-impact, patient-centered outcomes.